Lornoxicam

Drug Profile

Lornoxicam

Alternative Names: Bosporon; Chlortenoxicam; HN 10000; RO 139297; Safem; TS 110; Xefo

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Roche
  • Developer POZEN; Takeda Pharmaceuticals International GmbH
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuropathic pain; Osteoarthritis; Pain; Postoperative pain; Rheumatic disorders
  • Discontinued Migraine

Most Recent Events

  • 29 Mar 2012 Nycomed is now called Takeda Pharmaceuticals International
  • 30 Sep 2011 Nycomed has been acquired by Takeda
  • 30 Mar 2006 Lornoxicam is available for licensing in the US (http://www.pozen.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top